リツキシマブの世界市場

リツキシマブの世界市場は2030年までに112億米ドルに達する見込み

2024年に49億米ドルと推定されるリツキシマブの世界市場は、分析期間2024-2030年にCAGR 14.6%で成長し、2030年には112億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである皮下投与は、CAGR 15.3％を記録し、分析期間終了時には64億米ドルに達すると予測されます。静脈内投与セグメントの成長率は、分析期間中CAGR 13.2%と推定されます。

米国市場は13億米ドルと推定、中国はCAGR19.5％で成長予測

米国のリツキシマブ市場は2024年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに24億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは19.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ10.7%と13.1%と予測されています。欧州では、ドイツがCAGR 11.6%で成長すると予測されています。

世界のリツキシマブ市場- 主要動向と促進要因のまとめ

リツキシマブが標的生物学的製剤の進化する情勢の中で依然として強いのはなぜか？

CD20陽性B細胞を標的とするキメラモノクローナル抗体であるリツキシマブは、血液悪性腫瘍や自己免疫疾患の治療の要であり続けています。イントロダクションから20年経った現在でも、非ホジキンリンパ腫（NHL）、慢性リンパ性白血病（CLL）、関節リウマチ（RA）、多発血管炎性肉芽腫症などの適応症において確固たる存在感を示しています。より新しい生物学的製剤や低分子の代替薬の出現にもかかわらず、リツキシマブは、その実証された有効性、十分に文書化された安全性プロファイル、そして世界の第一選択治療ガイドラインへの組み入れにより、不可欠な存在であり続けています。

この薬剤は腫瘍学と免疫学の両分野で幅広く使用されているため、二重の市場優位性があります。CD20を標的とし、抗体依存性細胞傷害性（ADCC）および補体依存性細胞傷害性（CDC）を介してB細胞溶解を媒介するというそのメカニズムは、特にB細胞調節不全を示す患者において、臨床的に重要であり続けています。さらに、臨床試験では、全身性エリテマトーデス（SLE）や特発性血小板減少性紫斑病（ITP）のような適応外の疾患での使用が強化され続けており、その治療領域はさらに拡大しています。競合にもかかわらず、リツキシマブの持続的な臨床的有用性は、そのユニークな薬力学と管理可能な毒性に起因しており、併用レジメンにおける信頼性の高いツールとなっています。

バイオシミラーと皮下注製剤はどのように市場力学を再構築しているのか？

世界のリツキシマブ市場は、バイオシミラーの登場により構造的な変化を遂げつつあります。欧州、インド、日本、米国の規制当局の承認により、Truxima、Ruxience、Redituxといった費用対効果の高い代替品の参入が促進され、公的医療システムや民間の腫瘍クリニックで急速に普及しています。これらのバイオシミラー医薬品は、中低所得国における生物学的製剤へのアクセスの民主化に貢献し、オリジネーター企業に価格設定や販売戦略の見直しを迫っています。

もう一つの重要な動向は、静脈内投与から皮下投与への移行であり、これは患者の利便性を向上させ、病院のチェアタイムを短縮し、投与コストを下げることを目的としています。皮下投与のリツキシマブは、抗体をヒアルロニダーゼと結合させ、より速く吸収させるもので、いくつかの地域で臨床承認され、患者に好まれています。このシフトは、特に外来輸液センターの負担が大きい高所得国において、在宅投与モデルを促進しています。一方、化学療法サイクルを合理化し、複雑な治療レジメンにおけるコンプライアンスを向上させるために、リツキシマブと他の薬剤を組み合わせたキット製剤が検討されています。

需要の多様化を促進する適応症と地域市場は？

B細胞リンパ腫がリツキシマブの主要な領域であることに変わりはありませんが、自己免疫疾患での使用も加速しています。関節リウマチでは、特に血清陽性の患者において、TNF阻害剤に次ぐ第二選択薬としての役割を果たしています。また、血管炎症候群や多発性硬化症でも、特に他の疾患修飾薬に不耐性や非反応性の患者において、検討されることが多くなっています。このようなシフトは、複数の専門医による採用を促し、リツキシマブの使用を腫瘍科だけでなく、リウマチ科や神経内科にまで広げています。

地域別では、欧州がバイオシミラー医薬品の採用でリードしており、国家入札や公的保険制度により、基準薬であるリツキシマブからの代替が加速しています。インドとブラジルは、国内製造と国家調達プログラムにより、大幅な数量増加を示しています。一方、北米、特に米国では、バイオシミラーが病院の処方箋に急速に浸透しつつあるもの、依然として先発品のリツキサンが主流です。アフリカと東南アジアでは、需要が世界・アクセス・プログラムとWHOの事前承認に結びついており、リソースの限られた環境下でリンパ腫に対するリツキシマブの利用可能性が拡大しています。このように、価格設定、規制、臨床の慣行が異なる市場間で重層的な成長を遂げていることは、この薬剤が世界的に重要であることを強調しています。

市場拡大と治療の最適化を支えている戦略的要因とは？

リツキシマブ市場の成長は、リンパ増殖性疾患の有病率の増加、自己免疫疾患の診断向上、バイオシミラーの普及拡大、製剤の革新など、いくつかの要因によってもたらされています。リツキシマブは、悪性腫瘍と免疫疾患を対象とした治療ガイドラインに着実に盛り込まれているため、臨床医の信頼は揺るがず、広く使用されています。さらに、複数の炎症経路における早期B細胞の関与に対する認識が高まりつつあり、新たな自己免疫疾患への再ポジショニングを促しています。

医薬品戦略は、併用試験、実データ試験、バイオシミラーの最適化を通じてライフサイクルの延長に注力しています。いくつかのメーカーは、長期使用における安全性監視を強化するため、SC製剤の改良、合剤、AIを活用したファーマコビジランスに投資しています。一方、政府やNGOは、特に十分なサービスを受けていない市場において、がん医療アクセス・プログラムの下でリツキシマブ調達に資金を提供しています。このような研究開発、政策、アクセスにわたる総合的な取り組みが、リツキシマブの主力治療薬としての地位を維持すると同時に、競合や経済的圧力に直面する中でリツキシマブの進化を支えています。

セグメント

投与経路（皮下投与、静脈内投与、非経口投与）、流通チャネル（病院薬局、オンライン薬局、その他の流通チャネル）、用途（非ホジキンリンパ腫、慢性リンパ性白血病、関節リウマチ、その他の用途）

調査対象企業の例

• Amgen Inc.
• Amneal Pharmaceuticals
• Apotex Inc.
• Biocon Limited
• Bio-Thera Solutions
• Celltrion Healthcare Co. Ltd.
• Dr. Reddy's Laboratories
• Fresenius Kabi
• Glenmark Pharmaceuticals
• Hikma Pharmaceuticals
• Intas Pharmaceuticals Ltd.
• Mabion S.A.
• Mylan N.V.（Viatris）
• Novartis AG（Sandoz）
• Pfizer Inc.
• Reliance Life Sciences
• Roche Holding AG
• Samsung Bioepis
• Teva Pharmaceutical Industries
• Zydus Lifesciences Ltd.

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Rituximab Market to Reach US$11.2 Billion by 2030

The global market for Rituximab estimated at US$4.9 Billion in the year 2024, is expected to reach US$11.2 Billion by 2030, growing at a CAGR of 14.6% over the analysis period 2024-2030. Subcutaneous Administration, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$6.4 Billion by the end of the analysis period. Growth in the Intravenous Administration segment is estimated at 13.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 19.5% CAGR

The Rituximab market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 19.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.7% and 13.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.6% CAGR.

Global Rituximab Market - Key Trends & Drivers Summarized

Why Is Rituximab Still Holding Strong in the Evolving Landscape of Targeted Biologics?

Rituximab, a chimeric monoclonal antibody targeting CD20-positive B cells, continues to be a cornerstone in the treatment of hematological malignancies and autoimmune disorders. Even two decades after its introduction, it maintains a solid presence across indications such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis. Despite the emergence of newer biologics and small-molecule alternatives, rituximab remains indispensable due to its proven efficacy, well-documented safety profile, and inclusion in first-line therapy guidelines globally.

The drug's broad usage in both oncology and immunology offers it a dual-market advantage. Its mechanism-targeting CD20 to mediate B-cell lysis through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)-has remained clinically relevant, especially in patients exhibiting B-cell dysregulation. Moreover, clinical trials continue to reinforce its use in off-label conditions like systemic lupus erythematosus (SLE) and idiopathic thrombocytopenic purpura (ITP), further expanding its therapeutic footprint. Despite competition, rituximab’s enduring clinical utility is attributed to its unique pharmacodynamics and manageable toxicity, making it a reliable tool in combination regimens.

How Are Biosimilars and Subcutaneous Formulations Reshaping Market Dynamics?

The global rituximab market is undergoing a structural shift due to the advent of biosimilars. Regulatory approvals across Europe, India, Japan, and the U.S. have facilitated the entry of cost-effective alternatives such as Truxima, Ruxience, and Reditux, which have quickly gained traction in both public health systems and private oncology clinics. These biosimilars are helping to democratize access to biologic therapies in low- and middle-income countries and are compelling originator companies to revisit pricing and distribution strategies.

Another pivotal trend is the transition from intravenous (IV) to subcutaneous (SC) formulations, aimed at improving patient convenience, reducing hospital chair time, and lowering administration costs. Subcutaneous rituximab, combining the antibody with hyaluronidase for faster absorption, has gained clinical approval and patient preference in several regions. This shift is fostering home-based administration models, particularly in high-income countries with overburdened outpatient infusion centers. Meanwhile, combination products that include rituximab with other agents in pre-packaged kits are being explored to streamline chemotherapy cycles and enhance compliance in complex treatment regimens.

Which Indications and Regional Markets Are Driving Demand Diversification?

While B-cell lymphomas remain the primary domain for rituximab, its usage in autoimmune diseases is gaining pace. In rheumatoid arthritis, it serves as a second-line option after TNF inhibitors, especially in seropositive patients. It is also being increasingly considered for vasculitis syndromes and multiple sclerosis, particularly in patients with intolerance or non-responsiveness to other disease-modifying agents. This shift is encouraging multi-specialty adoption, extending rituximab use beyond oncology to rheumatology and neurology practices.

Regionally, Europe has led in biosimilar adoption, with national tenders and public insurance schemes accelerating substitution from reference rituximab. India and Brazil have seen significant volume growth driven by domestic manufacturing and state procurement programs. Meanwhile, North America-especially the U.S.-still sees dominant use of branded Rituxan, although biosimilars are rapidly encroaching into hospital formularies. In Africa and Southeast Asia, demand is tied to global access programs and WHO prequalification, which are expanding rituximab availability for lymphomas under resource-limited settings. This layered growth across markets with varied pricing, regulatory, and clinical practices underscores the drug's global relevance.

What Strategic Factors Are Sustaining Market Expansion and Therapy Optimization?

The growth in the rituximab market is driven by several factors, including increasing prevalence of lymphoproliferative disorders, improved diagnosis of autoimmune diseases, expanding biosimilar penetration, and formulation innovation. The steady inclusion of rituximab in evolving treatment guidelines for both malignancies and immune-mediated conditions ensures sustained clinician trust and widespread usage. Moreover, growing awareness of early B-cell involvement in multiple inflammatory pathways is encouraging its repositioning in newer autoimmune indications.

Pharmaceutical strategies are focusing on lifecycle extension through combination trials, real-world data studies, and biosimilar optimization. Several manufacturers are investing in SC formulation improvements, fixed-dose combinations, and AI-enabled pharmacovigilance to enhance safety monitoring in long-term use. Meanwhile, governments and NGOs are funding rituximab procurement under cancer care access programs, especially in underserved markets. These combined efforts-across R&D, policy, and access-are sustaining rituximab’s status as a mainstay therapy while supporting its evolution in the face of competitive and economic pressures.

SCOPE OF STUDY:

The report analyzes the Rituximab market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Subcutaneous Administration, Intravenous Administration, Parenteral Administration); Distribution Channel (Hospitals Pharmacy, Online Pharmacy, Other Distribution Channels); Application (Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application, Rheumatoid Arthritis Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Amgen Inc.
• Amneal Pharmaceuticals
• Apotex Inc.
• Biocon Limited
• Bio-Thera Solutions
• Celltrion Healthcare Co. Ltd.
• Dr. Reddy's Laboratories
• Fresenius Kabi
• Glenmark Pharmaceuticals
• Hikma Pharmaceuticals
• Intas Pharmaceuticals Ltd.
• Mabion S.A.
• Mylan N.V. (Viatris)
• Novartis AG (Sandoz)
• Pfizer Inc.
• Reliance Life Sciences
• Roche Holding AG
• Samsung Bioepis
• Teva Pharmaceutical Industries
• Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Rituximab - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Incidence of Non-Hodgkin's Lymphoma Throws the Spotlight on Rituximab-Based Therapies
  • Expansion of Autoimmune Disease Treatment Protocols Drives Adoption of Rituximab in Off-Label Use
  • Increased Preference for Targeted B-Cell Therapies Strengthens Business Case for Anti-CD20 Monoclonal Antibodies
  • Rising Global Access to Cancer Immunotherapy Expands Addressable Market for Rituximab Biosimilars
  • FDA and EMA Approvals of Biosimilar Variants Accelerate Cost-Effective Rituximab Adoption
  • Integration of Rituximab in First-Line and Maintenance Regimens Sustains Prescriber Confidence
  • Expansion of Hospital-Based Infusion Infrastructure Propels Rituximab Treatment Volume
  • Shift Toward Subcutaneous and Rapid Infusion Formulations Enhances Patient Convenience
  • Collaborative Oncology Care Models Drive Use of Rituximab in Multimodal Treatment Plans
  • Increased Reimbursement Coverage and Access Programs Support Market Penetration in Developing Regions
  • Emerging Clinical Evidence for Rituximab in Rare Autoimmune Disorders Expands Therapeutic Scope
  • R&D in Combination Therapy Trials Strengthens Value Proposition of Rituximab-Based Regimens
  • Pricing Pressures and Generic Competition Spur Market Entry of Cost-Accessible Biosimilar Brands
  • Surge in Personalized Oncology Approaches Highlights Role of Rituximab in Biomarker-Guided Protocols
  • Regulatory Harmonization Across Emerging Economies Enhances Biosimilar Approval Timelines
  • Pharma-Hospital Collaborations Drive Institutional Preference for Long-Term Rituximab Contracts
  • Increased Use in Pediatric Indications and Off-Label Autoimmune Treatments Fuels Volume Uptake
  • Rise in Hospital Day-Care and Ambulatory Cancer Clinics Promotes Rapid Rituximab Infusions
  • Biosimilar Adoption in Europe and Latin America Reshapes Competitive Landscape for Rituximab
  • Expansion of Pharmacovigilance and Real-World Evidence Strengthens Post-Marketing Confidence in Rituximab
  • Market Shift From Originator to Biosimilars Challenges Brand Loyalty but Expands Patient Access
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Rituximab Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Rituximab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Rituximab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Rituximab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Subcutaneous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Subcutaneous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Subcutaneous Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Intravenous Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Non-Hodgkin Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Non-Hodgkin Lymphoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Chronic Lymphocytic Leukemia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Chronic Lymphocytic Leukemia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Chronic Lymphocytic Leukemia Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Rheumatoid Arthritis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Hospitals Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• JAPAN
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• CHINA
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: China 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• EUROPE
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Rituximab by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Rituximab by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Rituximab by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• FRANCE
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: France 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• GERMANY
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Rituximab by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Rituximab by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Rituximab by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• INDIA
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: India 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Rituximab by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Rituximab by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Rituximab by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Rituximab by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Rituximab by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Rituximab by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030
• AFRICA
  • Rituximab Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Rituximab by Administration Route - Subcutaneous Administration, Intravenous Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Rituximab by Administration Route - Percentage Breakdown of Value Sales for Subcutaneous Administration, Intravenous Administration and Parenteral Administration for the Years 2014, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Rituximab by Application - Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Rituximab by Application - Percentage Breakdown of Value Sales for Other Applications, Non-Hodgkin Lymphoma Application, Chronic Lymphocytic Leukemia Application and Rheumatoid Arthritis Application for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Rituximab by Distribution Channel - Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Rituximab by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2014, 2025 & 2030

IV. COMPETITION